Business Context and Reporting Period
Rhythm Pharmaceuticals, Inc. filed this Form 8-K on November 9, 2018. The filing serves to recast financial information previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2017. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a change in accounting presentation regarding restricted cash. Consequently, no quantitative financial metrics are available in this text.
Material Changes Versus Prior Period
The material change involves the adoption of Accounting Standards Update (ASU) No. 2016-18, "Statement of Cash Flows (Topic 230): Restricted Cash," effective January 1, 2018. The Company has retrospectively applied this standard to its statements of cash flows for the years ended December 31, 2017, 2016, and 2015. The change requires that restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling beginning and end-of-period totals on the statement of cash flows.
Guidance, Outlook, and Risks
The filing contains no new guidance, outlook, or management commentary regarding future operations. It explicitly states that no other substantive changes have been made to the Form 10-K and that the filing should not be read to modify or update other disclosures. The document notes that it does not reflect events or occurrences after the filing of the original Form 10-K on March 12, 2018.
Investor Verification Checklist
- Verify the revised Consolidated Statements of Cash Flows for the years ended December 31, 2017, 2016, and 2015, as provided in Exhibit 99.1.
- Confirm that the reconciliation of cash and cash equivalents now includes restricted cash balances.
- Review the original Form 10-K filed on March 12, 2018, for all other financial data and operational updates not addressed in this 8-K.